NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01501149,Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ,https://clinicaltrials.gov/study/NCT01501149,CTTNKTL-Ⅲ/Ⅳ,UNKNOWN,"The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer (NK)/T Cell Lymphoma.",NO,Nasal and Nasal-type NK/T-cell Lymphoma,"DRUG: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DRUG: Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）","Progression-free survival, up to end of follow-up-phase (approximately 24 months)","response rate, 21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles., every 6 weeks,up to completion of treatment(approximately 18 weeks )|overall survival, up to the date of death (approximately 5 years)|median survival time, 24 months",,Mingzhi Zhang,"Second Hospital of Shanxi Medical University|Shanxi Province Cancer Hospital|Wuhan University|Wuhan TongJi Hospital|Wuhan Union Hospital, China|Qingdao University|Cancer Hospital of Guizhou Province|Xinyang Central Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,hnslblzlzx2011-2,2011-01,2015-12,2019-05,2011-12-29,,2015-07-17,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China",
